Tower Research Capital (TRC)’s Acutus Medical Inc AFIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-11,869
Closed -$2.23K – 6145
2024
Q1
$2.23K Buy
11,869
+105
+0.9% +$21 ﹤0.01% 5092
2023
Q4
$2.38K Sell
11,764
-2,353
-17% -$922 ﹤0.01% 5226
2023
Q3
$9.84K Buy
14,117
+1,205
+9% +$781 ﹤0.01% 4176
2023
Q2
$11.5K Buy
12,912
+5,140
+66% +$4.36K ﹤0.01% 3971
2023
Q1
$6K Buy
7,772
+7,694
+9,864% +$10K ﹤0.01% 4910
2022
Q4
$0 Sell
78
-127
-62% -$105 ﹤0.01% 6559
2022
Q3
$0 Sell
205
-10,985
-98% -$13.3K ﹤0.01% 6641
2022
Q2
$12K Buy
11,190
+4,007
+56% +$3.44K ﹤0.01% 4329
2022
Q1
$10K Buy
7,183
+3,905
+119% +$8.35K ﹤0.01% 4384
2021
Q4
$11K Buy
3,278
+1,549
+90% +$8.72K ﹤0.01% 4487
2021
Q3
$15K Buy
1,729
+359
+26% +$4.72K ﹤0.01% 4009
2021
Q2
$23K Sell
1,370
-2,132
-61% -$31.2K ﹤0.01% 3776
2021
Q1
$47K Buy
3,502
+3,073
+716% +$69.2K ﹤0.01% 3185
2020
Q4
$12K Sell
429
-1,291
-75% -$34.9K ﹤0.01% 4224
2020
Q3
$51K Buy
+1,720
New +$52.2K ﹤0.01% 3533

Other funds holding AFIB

Tower Research Capital (TRC)'s AFIB Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Acutus Medical Inc (AFIB) in Q2 2024, closing a stake of 11,869 shares — an estimated $2.23K sold.

Tower Research Capital (TRC) first reported a position in AFIB in Q3 2020 and held it in 15 quarters. The position peaked at $51K in Q3 2020. 1 fund tracked by Wall St. Rank holds AFIB as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Acutus Medical Inc position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 11,869 Acutus Medical Inc shares in Q2 2024, an estimated $2.23K.
  • Tower Research Capital (TRC) first reported a position in Acutus Medical Inc in Q3 2020 and held it in 15 quarters.
  • Tower Research Capital (TRC)'s Acutus Medical Inc position peaked at $51K in Q3 2020.
  • 1 fund tracked by Wall St. Rank held Acutus Medical Inc as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.